Opinion: Repeating elective cesarean delivery before 39 weeks can be risky

Article

Compared to birth at 39 weeks, elective CD at 37 to 38 weeks has been linked to several neonatal complications.

Alan Tita and his colleagues, who are part of the NICHD Maternal-Fetal Medicine Units Network, recently attempted to better delineate the risks of elective CD at term but prior to 39 weeks.4 They studied over 13,000 women with singleton pregnancies who underwent elective repeat CD at term. The primary outcome was a composite of neonatal death and any of several other adverse sequelae, including respiratory complications, treated hypoglycemia, newborn sepsis, and admission to the neonatal intensive care unit (NICU). As compared with births at 39 completed weeks (>39 0/7), births at 37 and 38 weeks were associated with an increased risk of the primary outcome. The adjusted odds ratio (OR) for adverse outcomes among births at 37 weeks was 2.1 (95% CI; 1.7–2.5) and for births at 38 weeks, it was 1.5 (95% CI; 1.3–1.7). The rates of adverse respiratory outcomes, mechanical ventilation, newborn sepsis, hypoglycemia, admission to the NICU, and hospitalization for 5 days or more were increased by a factor of 1.8 to 4.2 for births at 37 weeks and 1.3 to 2.1 for births at 38 weeks.

The study's most alarming observation was that when the analysis was restricted to the 52% of deliveries that occurred just during the last 3 days before 39 completed weeks (i.e., from 38, weeks 4 days to 38 weeks, 6 days), the risk of complications remained elevated compared with deliveries at 39 completed weeks (RR, 1.21; 95% CI; 1.04–1.40). This suggests that even a few days may make a significant difference. To put this in absolute terms, at 38 weeks, 1.9% of babies had respiratory distress syndrome, 3.9% had transient tachypnea, and over 8% were admitted to the NICU. Tita's research buttresses prior observations that elective CD without antecedent labor is an independent risk factor for respiratory complications in the newborn, and that this risk is increased before 39 weeks.1,5-9

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.